10.2 Medical Management of Male LUTS / BPO

10.2 Medical Management of Male LUTS / BPO

Pharmacotherapy is an initial option for bothersome moderate-to-severe male lower urinary tract symptoms (LUTS), after assessment for complications and causes requiring other treatment. Lifestyle measures accompany treatment; LUTS do not by themselves prove benign prostatic obstruction (BPO). Current European Association of Urology (EAU) guidelines emphasize a phenotype-driven approach: tailoring drug selection to symptom severity, predominant symptom subtype (voiding vs storage), anatomical prostate volume, baseline serum PSA, post-void residual (PVR), and individual risk of disease progression.

---

1. Therapeutic Goals & Disease Progression Risk Stratification

The overarching goals of medical intervention are twofold:

1. Short-Term Goal: Rapidly alleviate bothersome voiding and storage symptoms and optimize health-related quality of life.
2. Long-Term Goal: Prevent clinical disease progression, specifically the development of acute urinary retention (AUR), recurrent urinary tract infections, post-renal renal failure, and the need for BPH-related surgical intervention.

Clinical Progression Risk Factors

Larger prostate volume, higher PSA, older age, more severe symptoms, reduced flow and increasing residual urine can help assess progression risk. IPSS 20–35 is severe, but no single age or PVR threshold mandates disease-modifying medication.

Offer 5-ARI or alpha-blocker/5-ARI combination to men with moderate-to-severe symptoms and increased progression risk, for example prostate volume >40 mL. PSA can support volume/risk assessment when testing will influence care; an elevated PSA is not a separate mandatory criterion if enlargement is documented. Balance expected benefit, slow onset, adverse effects and patient preference.

---

2. Alpha-1 Adrenoceptor Antagonists (Alpha-Blockers)

Alpha-1 blockers are the most widely prescribed first-line agents for moderate-to-severe male LUTS. They act by antagonizing post-junctional alpha-1 adrenergic receptors located within the prostatic stroma, prostatic capsule, and bladder neck, attenuating the dynamic component of bladder outlet obstruction without compromising detrusor contractility.

Pharmacological Profiles & Subtype Selectivity

Clinical Efficacy & Critical Limitations

• Rapid Onset: Benefit can begin within hours to days; the full symptomatic effect generally develops over several weeks.
• Symptom Reduction: Alpha-blockers reduce IPSS by 30% to 40% (4 to 6 points). Placebo responses in LUTS trials are substantial, so change from baseline is not the same as the drug-specific treatment effect.
• Uroflowmetry: Maximum urinary flow rate improves by 20% to 25% (~2.0 to 3.0 mL/s).

Adverse Effects

1. Vasodilatory Complications: Orthostatic hypotension, postural dizziness, asthenia, nasal congestion, and peripheral edema. These complications stem from antagonism of vascular alpha-1B receptors. They are most pronounced with non-selective agents (doxazosin, terazosin) and minimal with uroselective agents (tamsulosin, silodosin, alfuzosin).
2. Ejaculatory Dysfunction: Reduced or absent seminal emission is a common explanation for alpha-blocker-associated ejaculatory dysfunction; it should not automatically be described as retrograde ejaculation. Anejaculation is strongly correlated with receptor selectivity, occurring in ~28% of patients taking silodosin and ~10% taking tamsulosin. Ejaculatory dysfunction is usually reversible after stopping treatment. Counsel patients about this effect; it is not a required clinical test of treatment response.
3. Intraoperative Floppy Iris Syndrome (IFIS): First described by Chang and Campbell in 2005, IFIS is a surgical crisis encountered during cataract phacoemulsification characterized by a classic triad:
   • Flaccid iris stroma that undulates and billows in response to ordinary irrigation currents.
   • Progressive intraoperative pupillary constriction (miosis) despite pre-operative pharmacological mydriatics.
   • Propensity for the flaccid iris stroma to prolapse toward the corneal phacoemulsification incisions.

IFIS results from chronic blockade of alpha-1A adrenoceptors located on the iris dilator pupillae muscle, leading to long-term muscular atrophy. While most strongly associated with tamsulosin, IFIS has been documented with every alpha-blocker. Stopping an alpha-blocker before cataract surgery does not reliably prevent IFIS; previous exposure remains important. Patients must be instructed to inform their ophthalmologist of any current or previous alpha-blocker exposure prior to lens surgery, enabling the surgeon to utilize stabilizing maneuvers (iris retractors, pupil expansion rings like Malyugin rings, or intracameral phenylephrine).

---

3. 5-Alpha-Reductase Inhibitors (5-ARIs)

5-ARIs are disease-modifying agents that target the underlying endocrine etiology of BPH by blocking the enzymatic conversion of testosterone to dihydrotestosterone (DHT) within target tissues.

Finasteride vs. Dutasteride

• Finasteride (5 mg daily): Competitive, selective inhibitor of the 5AR Type 2 isoenzyme. It suppresses circulating serum DHT by ~70% and intraprostatic DHT by ~85% to 90%.
• Dutasteride (0.5 mg daily): Dual competitive inhibitor of both 5AR Type 1 and Type 2 isoenzymes. It suppresses serum DHT by approximately 95%. Both agents markedly suppress prostatic DHT; stronger serum suppression does not establish superior clinical outcomes.

In the 12-month EPICS trial, finasteride 5 mg and dutasteride 0.5 mg produced similar improvements in prostate volume, symptoms and Qmax. This comparison did not establish equivalent long-term protection against AUR or surgery.

Clinical Efficacy & Disease Modification

1. Slow Clinical Onset: Because 5-ARIs act by triggering apoptosis in the androgen-dependent glandular epithelium, clinical symptom reduction is slow. Noticeable therapeutic benefit requires at least 3 to 6 months of continuous treatment, with maximal clinical and anatomical effects reached at 1 to 2 years.
2. Prostate Volume Reduction: 5-ARIs induce a 20% to 30% reduction in total prostate volume.
3. Prevention of Progression: Long-term randomized trials (PLESS, MTOPS, CombAT) have definitively demonstrated that 5-ARIs reduce the 4-year relative risk of acute urinary retention (AUR) by ~57% to 68% and the risk of BPH-related surgery by 55% in PLESS and 64% in MTOPS versus placebo.
4. Patient Selection: Use 5-ARIs for moderate-to-severe LUTS with increased progression risk, such as prostate volume >40 mL. Benefit depends on initial size; dutasteride has evidence in the 30–40-mL range. PSA may help estimate enlargement and risk, but is not a mandatory second threshold. Small glands offer less expected benefit, so 5-ARIs are not routine symptom treatment for men without enlargement.

Impact on Serum PSA & Prostate Cancer Surveillance

Continuous administration of a 5-ARI decreases total serum PSA concentrations by approximately 50% after 6 months of therapy. To properly evaluate serum PSA for prostate cancer detection in a patient taking a 5-ARI:

Adverse Events

5-ARIs are generally well-tolerated, but cause sexual adverse effects in a minority of men: decreased libido (~3–5%), erectile dysfunction (~5–8%), ejaculatory disorders (~1–3%), and gynecomastia or breast tenderness (~1–2%). These side effects peak during the first year of therapy and diminish thereafter.

---

4. Combination Therapy: The Landmark Trials (MTOPS & CombAT)

Given that alpha-blockers provide immediate symptomatic relief without halting progression, whereas 5-ARIs slow progression but require months to relieve symptoms, combining both drug classes represents an intuitive, synergistic strategy.

+-----------------------------------------------------------------------------------+
|                         LANDMARK COMBINATION THERAPY TRIALS                       |
+-----------------------------------------------------------------------------------+
|  MTOPS TRIAL (NEJM 2003)                                                          |
|  - 3,047 men followed for a mean of 4.5 years.                                    |
|  - Doxazosin + Finasteride vs. Doxazosin alone vs. Finasteride alone vs. Placebo. |
|  - Combination reduced overall clinical progression by 66% (p < 0.001).           |
|  - Risk of AUR reduced by 81% (combination) vs 68% (finasteride).                 |
|  - Doxazosin alone failed to reduce the long-term risk of AUR or surgery.         |
+-----------------------------------------------------------------------------------+
                                          |
                                          v
+-----------------------------------------------------------------------------------+
|  CombAT TRIAL (Eur Urol 2010)                                                     |
|  - 4,844 men (prostate >= 30 mL, PSA >= 1.5 ng/mL) followed for 4 years.          |
|  - Tamsulosin + Dutasteride vs. Tamsulosin alone vs. Dutasteride alone.           |
|  - Combination reduced relative risk of AUR or BPH surgery by 65.8% vs tamsulosin.|
|  - Symptoms/flow better than either alone; AUR/surgery vs dutasteride not significant.|
+-----------------------------------------------------------------------------------+

The MTOPS Study (Medical Therapy of Prostatic Symptoms)

Published in 2003, MTOPS randomized 3,047 men over an average follow-up of 4.5 years into four treatment arms: placebo, doxazosin, finasteride, or combination therapy. Overall clinical progression (defined primarily by a >=4-point increase in IPSS) was reduced by 39% with doxazosin alone, 34% with finasteride alone, and 66% with combination therapy compared to placebo. Against placebo, finasteride reduced AUR by 68% and invasive therapy by 64%; combination reduced these endpoints by 81% and 67%, respectively. Doxazosin did not significantly reduce their long-term incidence.

The CombAT Study (Combination of Avodart and Tamsulosin)

Published in 2010, CombAT evaluated 4,844 men with documented BPE (prostate volume >= 30 mL and PSA >= 1.5 ng/mL) randomized to tamsulosin 0.4 mg, dutasteride 0.5 mg, or daily combination therapy over 4 years. Combination therapy reduced the relative risk of AUR or BPH-related surgery by 65.8% compared to tamsulosin monotherapy and by 19.6% compared to dutasteride monotherapy; the latter difference was not statistically significant (p=0.18). Furthermore, combination therapy provided significantly greater and more sustained IPSS improvements (-6.3 points) and Qmax increases than either monotherapy.

EAU Guideline Recommendations for Combination Therapy

• Combination therapy (alpha-blocker + 5-ARI) is strongly recommended for men with moderate-to-severe LUTS and increased progression risk, for example prostate volume >40 mL, who accept long-term treatment. CombAT entry criteria are not mandatory paired EAU treatment thresholds.
• De-escalation Strategy: In patients who achieve clinical stabilization after 6 to 9 months of combination therapy, discontinuing the alpha-blocker while continuing 5-ARI monotherapy can be considered. However, men with severe baseline symptoms may benefit from longer combination treatment; monitor for deterioration after withdrawal.

---

5. Storage Symptoms: Antimuscarinics & Beta-3 Adrenoceptor Agonists

Storage symptoms (urgency, frequency and nocturia) are common in men with LUTS. They can accompany obstruction or arise from bladder and systemic causes; symptoms alone do not prove secondary detrusor overactivity. Historically, clinicians feared that administering bladder-relaxing agents to obstructed men would paralyze the detrusor and precipitate acute urinary retention. Extensive contemporary randomized trial evidence has overturned this historical dogma.

Antimuscarinic Agents

• Agents: Solifenacin, Tolterodine, Fesoterodine, Oxybutynin.
• Mechanism: Competitive antagonists of muscarinic M2 and M3 receptors located on detrusor smooth muscle, attenuating acetylcholine-mediated uninhibited contractions during the storage phase.
• Clinical Profile: When prescribed as monotherapy or combined with an alpha-blocker (e.g., NEPTUNE evaluated tamsulosin plus solifenacin; PLUS evaluated tamsulosin plus mirabegron, not an antimuscarinic), antimuscarinics significantly reduce urgency episodes, daytime frequency, and urgency incontinence.
• Safety Threshold: AUR is uncommon in selected men with baseline PVR <150 mL, but residuals can increase. Reassess symptoms and PVR, and stop/review treatment if the urinary stream deteriorates. EAU weakly advises against antimuscarinics when PVR >150 mL; a lower residual does not guarantee safety.

Beta-3 Adrenoceptor Agonists (Mirabegron)

• Mechanism: Mirabegron selectively stimulates beta-3 adrenoceptors located in the detrusor smooth muscle of the bladder dome. Beta-3 stimulation activates adenylyl cyclase, elevating intracellular cAMP and inducing detrusor relaxation during the filling phase without impairing detrusor contractility during voiding.
• Clinical Profile: When added to an alpha-blocker (e.g., the MATCH and PLUS studies), mirabegron can modestly improve persistent storage symptoms. PLUS used 25 mg increasing to 50 mg daily and found no clinically important average Qmax/PVR deterioration, but six men (1.7%) developed urinary retention. Monitor voiding, particularly with significant BOO.
• Advantages over Antimuscarinics: Mirabegron avoids antimuscarinic burden and generally causes less dry mouth, making it an option when those adverse effects matter. It is not automatically the preferred drug for every older patient. Measure blood pressure before treatment and periodically thereafter. It is contraindicated in patients with severe uncontrolled hypertension (systolic >= 180 mmHg or diastolic >= 110 mmHg).

---

6. Phosphodiesterase Type 5 (PDE5) Inhibitors

Daily administration of the long-acting PDE5 inhibitor tadalafil (5 mg once daily) is approved and recommended by EAU guidelines for the treatment of moderate-to-severe male LUTS with or without concurrent erectile dysfunction (ED).

Mechanism of Action in LUTS

Tadalafil increases intracellular cyclic guanosine monophosphate (cGMP) by blocking its degradation by PDE5. Proposed contributions to LUTS benefit include:

1. Reduced intracellular calcium, promoting smooth muscle relaxation in the prostatic stroma, bladder neck, and pelvic vasculature.
2. Improved pelvic perfusion.
3. Modulation of afferent bladder/prostate signaling.
4. Possible anti-inflammatory effects.

These downstream explanations are not all established clinical mechanisms of symptom relief.

Clinical Efficacy & Profile

Tadalafil 5 mg daily achieves a clinically meaningful IPSS improvement and can have symptom efficacy similar to alpha-blockers, alongside significant improvements in erectile function (IIEF score). However:

---

7. Phytotherapy

Phytotherapeutic preparations (herbal remedies) are widely consumed by men across Europe. The most common botanical extracts derive from Serenoa repens (saw palmetto berry), Pygeum africanum (African plum tree bark), and Cucurbita pepo (pumpkin seed).

EAU Guideline Position

Botanical extracts are complex chemical mixtures whose biological activity depends entirely on the extraction method used (solvents include hexane, ethanol, or supercritical carbon dioxide). Different commercial brands contain vastly different concentrations of free fatty acids, phytosterols, and flavonoids. Consequently, trials cannot be generalized across brands.

• General Phytotherapy: EAU guidelines do not recommend unstandardized or generic plant extracts for the management of male LUTS due to contradictory trial results and lack of manufacturing uniformity.
• Hexanic Extract of Serenoa repens (HESr): A specific, standardized hexanic lipidosterolic extract of Serenoa repens (e.g., Permixon) has putative anti-inflammatory and anti-androgenic actions; laboratory mechanisms do not establish clinical efficacy. Evidence is extract-specific and heterogeneous. EAU weakly offers HESr to men wishing to avoid adverse effects, particularly sexual effects, and strongly recommends counselling that benefit may be modest.

---

Comparison of Pharmacological Classes in Male LUTS / BPO